Blocking CXCL12/CXCR4 axis, an upstream regulator of ERK1/2 and AKT /mTOR signaling, with AMD3100 of CXCR4’s specific antagonist could counteract the hyperactivation of atrial fibrosis and reduce AF susceptibility [60]. This evidence concerns the gene CXCR4 and atrial fibrillation.